Company news
Profusa, Inc. news in 2026
Profusa, Inc.'s news releases, calls and decks from 2026, newest first.
Profusa Receives ISO 13485: 2016 Certificate from GMED
October 15, 2026
Profusa, Inc. Receives Nasdaq Compliance Determination
September 15, 2026
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
August 31, 2026
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
August 20, 2026
Profusa Announces 1-for-4 Reverse Stock Split
August 13, 2026
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
July 31, 2026
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
July 27, 2026
Profusa Announces 1-for-25 Reverse Stock Split
July 1, 2026
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
June 24, 2026
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
June 12, 2026
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
June 10, 2026
Profusa Announces Listing Transfer to The Nasdaq Capital Market
May 15, 2026
Profusa Receives Favorable Nasdaq Listing Determination
May 8, 2026
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
May 5, 2026
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
April 6, 2026
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
February 27, 2026
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance
February 18, 2026
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
February 13, 2026
Profusa Announces 1-for-75 Reverse Stock Split
February 4, 2026
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
January 29, 2026
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
January 15, 2026
Profusa Adds Leading Greek Vascular Surgeon to Customer Base
January 8, 2026